These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21684427)

  • 21. Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field.
    Hendriks J
    Vaccine; 2012 Sep; 30(44):6230-40. PubMed ID: 22902679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innovative vaccine production technologies: the evolution and value of vaccine production technologies.
    Bae K; Choi J; Jang Y; Ahn S; Hur B
    Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achieving clinical equality in an influenza pandemic: patent realities.
    Kane EM
    Seton Hall Law Rev; 2009; 39(4):1137-72. PubMed ID: 20718133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.
    Dalençon F
    Hum Vaccin Immunother; 2013 Sep; 9(9):2013-4. PubMed ID: 23938771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
    Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
    Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translation of an experimental oral vaccine formulation into a commercial product.
    Carter KC; Ferro VA; Alexander J; Mullen AB
    Methods; 2006 Feb; 38(2):65-8. PubMed ID: 16406571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saponin-adjuvanted particulate vaccines for clinical use.
    Skene CD; Sutton P
    Methods; 2006 Sep; 40(1):53-9. PubMed ID: 16997713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine adjuvants: scientific challenges and strategic initiatives.
    Harandi AM; Davies G; Olesen OF
    Expert Rev Vaccines; 2009 Mar; 8(3):293-8. PubMed ID: 19249971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steve Reed. Interviewed by Charlotte Schubert.
    Schubert C
    Nat Biotechnol; 2009 Nov; 27(11):971-2. PubMed ID: 19898441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
    Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
    Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine process technology.
    Josefsberg JO; Buckland B
    Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Technology transfer to developing country vaccine manufacturers to improve global influenza vaccine production: a success story and a window into the future.
    LaForce FM
    Vaccine; 2011 Jul; 29 Suppl 1():A1. PubMed ID: 21684419
    [No Abstract]   [Full Text] [Related]  

  • 37. ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation.
    Lövgren Bengtsson K; Morein B; Osterhaus AD
    Expert Rev Vaccines; 2011 Apr; 10(4):401-3. PubMed ID: 21506635
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvants for malaria vaccines.
    Coler RN; Carter D; Friede M; Reed SG
    Parasite Immunol; 2009 Sep; 31(9):520-8. PubMed ID: 19691556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive hands-on training for influenza vaccine manufacturing: a WHO-BARDA-BTEC partnership for global workforce development.
    Ruiz J; Gilleskie GL; Brown P; Burnett B; Carbonell RG
    Biochem Mol Biol Educ; 2014; 42(5):414-9. PubMed ID: 25132407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.